(RTTNews) - Cytokinetics, Inc. (CYTK), a biopharmaceutical company focused on muscle biology, on Monday announced the launch of the AMBER-HFpEF trial, a Phase 2 clinical study to evaluate CK-586 in patients with symptomatic heart failure with preserved ejection fraction or HFpEF.
CK-586 is a cardiac myosin inhibitor in development for the treatment of a subgroup of HFpEF patients who exhibit hypercontractility and ventricular hypertrophy.
The AMBER-HFpEF trial is a randomized, double-blind, placebo-controlled, multi-center study designed to assess the safety, tolerability, and efficacy of CK-586.
This trial builds on promising data from previous studies in related conditions such as non-obstructive hypertrophic cardiomyopathy or nHCM.
The trial aims to provide further insights into CK-586's potential to improve heart function and symptoms in patients with HFpEF, a condition that significantly impacts quality of life and has a poor prognosis despite advances in heart failure treatments.
Cytokinetics plans to enroll approximately 60 patients across three escalating doses to evaluate CK-586's effects on key cardiovascular markers.
The trial marks a critical step in the company's goal to provide targeted, effective therapies for heart failure patients with preserved ejection fraction.
Currently, CYTK is trading at $45.70 down by 0.09%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
